NCT04120753已完成4 期
A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease
Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2019年8月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 106
- 试验地点
- 1
- 主要终点
- mLDL-C change rate
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of OLOMAX Tab (20/5/5mg, 20/5/10mg) in Hypertension Patients with Low-Intermediate Risk for Cardiovascular Disease.
详细描述
The patients who meet the inclusion/exclusion criteria will be randomized 1:1:1 to test group 1 (olomax tablet 20/5/5mg), test group 2 (olomax tablet 20/5/10mg), and control group (sevica tablet 5/20mg.
After randomization, the drug will be administered for 8 weeks according to the assigned group.
During the administration period, subjects will conduct a total of three outpatient visits at 4 weeks (Visit 3) and 8 weeks (Visit 4, EOS), including randomized visits (Visit 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Screening (Visit 1) Inclusion Criteria
- •Men and women over 19 years of age as of the date of written consent
- •High blood pressure patients who meet the following criteria - In case of new arrivals, Sitting systolic blood pressure (sitSBP) ≥ 160 mmHg or sitting diastolic blood pressure (sitDBP) ≥ 100 mmHg, or
- •If you are taking one antihypertensive drug from the Angiotensin II Receptor Blocker (ARB) or Calcium-Channel Blocker (CCB) class, sitSBP ≥ 140 mmHg or sitDBP ≥ 90 mmHg, or
- •If you are taking ARB and CCB class antihypertensive drugs together
- •Those who meet the following mLDL-C criteria* (*Korean Society of Lipid and Atherosclerosis Dyslipidemia Treatment Guideline 3)
- •For cardiovascular disease low risk group #1, LDL-C ≥ 130 mg/dL or
- •For intermediate risk group #2 for cardiovascular disease, LDL-C ≥ 100 mg/dL. #1: Low-risk group: Those who do not have the following major cardiovascular risk factors other than high blood pressure
- •#2: Moderate risk group: People with one or more of the following major cardiovascular risk factors other than hypertension
- •Age (men ≥45 years, women ≥55 years)
- •Family history of early onset coronary artery disease (coronary artery disease occurs in family members [parents, siblings] <55 years old for men and <65 years old for women)
- •High density lipoprotein-cholesterol (HDL-C) <40 mg/dL (However, in case of HDL-C ≥60 mg/dL, 1 is subtracted from the number of major risk factors.)
- •Those who voluntarily agree to participate in clinical trials and sign a written consent form
- •Random allocation (visit 2) Inclusion criteria
- •Those who have medication compliance of more than 70% during the introduction period of Sevica Tablet 5/20 mg and have good TLC performance according to the investigator's judgment
- •Those who meet the following test values for each institution at the time of the baseline (visit 2) visit ① For low-risk cardiovascular disease group, mLDL-C ≥ 130 mg/dL or For those at moderate risk for cardiovascular disease, mLDL-C ≥ 100 mg/dL
排除标准
- •Patient with hypersensitivity Olmesartan, Amlodipine, Rosuvastatin, dihydropyridine
- •Who disagreed to perform effective contraception during the clinical trial
- •Orthostatic hypotension with symptoms
- •Secondary hypertension and suspected secondary hypertension
- •Creatinine clearance < 30mL/min
- •AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x ULN (upper limit of normal range)
- •Patients with hypersensitivity to the main ingredient (Olmesartan, Amlodipine or Rosuvastatin) or components of the investigational drug or dihydropyridine derivatives
- •Pregnant and lactating women, women and men of childbearing potential who do not agree to use appropriate contraception during the clinical trial period
- •Implantation of an intrauterine device or intrauterine system, ② Double barrier method for men or women of childbearing potential (condoms and contraceptive diaphragms, vaginal sponges or cervical caps), ③ Sterilization procedures (vasectomy, bilateral tubal ligation, etc.)
- •Patients with symptomatic orthostatic hypotension
- •Patients with secondary hypertension or patients suspected of having secondary hypertension (e.g. aortic coarctation, hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc.)
- •Those with confirmed medical history, concomitant diseases, or surgical history/procedure history:
- •① The following cardiovascular disease occurred within 24 weeks from the time of screening
- •Coronary artery disease, atherosclerotic ischemic stroke and transient cerebral ischemic attack, peripheral artery disease, carotid artery disease (limited to cases where significant carotid artery stenosis is confirmed), abdominal aneurysm, severe aortic stenosis, coronary artery revascularization (PTCA or CABG) , Arrhythmias requiring treatment (ventricular tachycardia, etc.)
- •Myopathy, including rhabdomyolysis, that occurred within 24 weeks from the time of screening
- •③ Biliary obstruction occurring within 24 weeks from the time of screening
- •Severe liver failure that occurred within 24 weeks from the time of screening ⑤ Drug or alcohol abuse within 1 year from the time of screening ⑥ Major mental illness (depression, bipolar disorder, etc.) ⑦ Malignant tumor within 5 years from the time of screening 6) Persons confirmed to have abnormalities in the following laboratory tests at the time of screening and randomization ① CK ≥ 2
- •Triglyceride (TG) ≥ 500 mg/dL ③ Active liver disease including persistent ALT elevation of unknown cause or AST ≥ 3 ④ The following renal function abnormalities:
- •Kidney dialysis or
- •Patients with severe renal impairment (creatinine clearance (CLcr) < 30 mL/min)
- •Hyperkalemia (K >5.5 mEq/L)
- •Hyponatremia (Na <135 mEq/L) or uncorrected sodium depletion ⑦ Hyperuricemia (Uric acid >10 mg/dL) 7) Those who have taken statin drugs or non-statin lipid regulators within 8 weeks before screening 8) Those expected to be administered the following drugs during the clinical trial period, including screening
- •Aliskiren ② Cyclosporine ③ Statin preparations other than clinical investigational drugs ④ Vistatin lipid regulators other than clinical investigational drugs
- •Antihypertensive drugs other than clinical investigational drugs ⑥ Other drugs that may affect blood lipids 9) People with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 10) A person who has received another investigational drug or a clinical trial medical device within 30 days before screening 11) Other people deemed unsuitable for participation in clinical trials according to the judgment of the investigator
研究组 & 干预措施
Treatment 3
Active Comparator
Olmesartan 20 mg/Amlodipine 5 mg
干预措施: Olmesartan 20 mg/Amlodipine 5 mg (Drug)
Treatment 1
Experimental
OLOMAX 20/5/5mg
干预措施: OLOMAX 20/5/5mg (Drug)
Treatment 2
Experimental
OLOMAX 20/5/10mg
干预措施: OLOMAX 20/5/10mg (Drug)
结局指标
主要结局
mLDL-C change rate
时间窗: 8 weeks
mLDL-C change rate (%) at 8 weeks after administration compared to baseline in test group 2 and control group
mLDL-C change rate (%)
时间窗: 8 weeks
mLDL-C change rate (%) at 8 weeks after administration compared to baseline in test group 1 and control group
次要结局
- cLDL-C* change rate(8 weeks)
- Proportion of test subjects with mLDL-C less than 70 mg/dL(8 weeks)
- Change and rate of change in sitDBP (%)(8 weeks)
- Blood pressure normalization* rate (%(8 weeks)
- Change amount and rate of change (%)(8 weeks)
- Change rate (%) in mLDL-C(4 weeks)
- Change amount and rate of change (%) in each of the following lipid indicators(8 weeks)
- Proportion of test subjects with mLDL-C less than 100 mg/dL(8 weeks)
- Change and rate of change in sitSBP (%)(4 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and AdolescentsEpilepsyNCT01431976GlaxoSmithKline20
终止
1 期
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)ALSFTDFrontotemporal DementiaAmyotrophic Lateral SclerosisNCT05683860Wave Life Sciences USA, Inc.8
招募中
1 期
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)Platinum-resistant Ovarian Cancer (PROC)Hepatocellular Carcinoma (HCC)Colorectal Cancer (CRC)HER2 Negative Breast CancerRenal Cell Carcinoma (RCC)Cutaneous MelanomaNCT05824975GI Innovation, Inc.358
终止
3 期
Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsPost-Operative PainAcute PainNCT02687451Endo Pharmaceuticals28
已完成
3 期
Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute DiarrheaDiarrheaNCT03463512Abbott124